480 related articles for article (PubMed ID: 34566999)
1. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
Front Immunol; 2021; 12():733958. PubMed ID: 34566999
[TBL] [Abstract][Full Text] [Related]
2. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody.
Richardson SI; Lambson BE; Crowley AR; Bashirova A; Scheepers C; Garrett N; Abdool Karim S; Mkhize NN; Carrington M; Ackerman ME; Moore PL; Morris L
PLoS Pathog; 2019 Dec; 15(12):e1008064. PubMed ID: 31841557
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
4. Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth.
van Dorsten RT; Wagh K; Moore PL; Morris L
Front Immunol; 2021; 12():734110. PubMed ID: 34603312
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
Front Immunol; 2021; 12():670561. PubMed ID: 35003053
[TBL] [Abstract][Full Text] [Related]
6. Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies.
Kim S; Filsinger Interrante MV; Kim PS
J Virol; 2023 Jan; 97(1):e0164722. PubMed ID: 36541800
[TBL] [Abstract][Full Text] [Related]
7. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
Sacks D; Wiehe K; Morris L; Moore PL
J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865
[TBL] [Abstract][Full Text] [Related]
8. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
[TBL] [Abstract][Full Text] [Related]
9. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
Richardson SI; Chung AW; Natarajan H; Mabvakure B; Mkhize NN; Garrett N; Abdool Karim S; Moore PL; Ackerman ME; Alter G; Morris L
PLoS Pathog; 2018 Apr; 14(4):e1006987. PubMed ID: 29630668
[TBL] [Abstract][Full Text] [Related]
10. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.
Doria-Rose NA; Bhiman JN; Roark RS; Schramm CA; Gorman J; Chuang GY; Pancera M; Cale EM; Ernandes MJ; Louder MK; Asokan M; Bailer RT; Druz A; Fraschilla IR; Garrett NJ; Jarosinski M; Lynch RM; McKee K; O'Dell S; Pegu A; Schmidt SD; Staupe RP; Sutton MS; Wang K; Wibmer CK; Haynes BF; Abdool-Karim S; Shapiro L; Kwong PD; Moore PL; Morris L; Mascola JR
J Virol; 2016 Jan; 90(1):76-91. PubMed ID: 26468542
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
[TBL] [Abstract][Full Text] [Related]
12. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
13. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
[TBL] [Abstract][Full Text] [Related]
14. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
15. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.
Moldt B; Schultz N; Dunlop DC; Alpert MD; Harvey JD; Evans DT; Poignard P; Hessell AJ; Burton DR
J Virol; 2011 Oct; 85(20):10572-81. PubMed ID: 21849450
[TBL] [Abstract][Full Text] [Related]
16. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
[TBL] [Abstract][Full Text] [Related]
17. Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.
Phelps M; Balazs AB
Front Immunol; 2021; 12():734304. PubMed ID: 34603314
[TBL] [Abstract][Full Text] [Related]
18. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
[TBL] [Abstract][Full Text] [Related]
19. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
20. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
Front Immunol; 2018; 9():3163. PubMed ID: 30697215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
